Akademska digitalna zbirka SLovenije - logo
E-viri
  • COVID-19 and Cardiovascular...
    Clerkin, Kevin J; Fried, Justin A; Raikhelkar, Jayant; Sayer, Gabriel; Griffin, Jan M; Masoumi, Amirali; Jain, Sneha S; Burkhoff, Daniel; Kumaraiah, Deepa; Rabbani, LeRoy; Schwartz, Allan; Uriel, Nir

    Circulation (New York, N.Y.), 2020-May-19, 2020-05-19, 20200519, Letnik: 141, Številka: 20
    Journal Article

    Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.